(Q79139530)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

title

Dasatinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Peter Kirkpatrick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Hagop Kantarjian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Elias Jabbour

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Joanne Grimley

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

19 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

717-718

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

cites work

Chronic myeloid leukemia

1 reference

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

31 March 2020

1 reference

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

31 March 2020

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

31 March 2020

1 reference

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

31 March 2020

1 reference

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

31 March 2020

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

31 March 2020

1 reference

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

31 March 2020

1 reference

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

31 March 2020

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2135

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17001803%20AND%20SRC:MED&resulttype=core&format=json